Table 2.
Outcome and management of Covid-19 among CLL patients (n = 60) in two time periods.
| All patients | Admitted month 1–6 of the pandemic | Admitted month 7–13 of the pandemic | |
|---|---|---|---|
| Hospital admission | 77% (46/60) | 86% (19/22) | 71% (27/38) |
| ICU admission | 24% (11/46) | 37% (7/19) | 15% (4/27) |
| Death (if admitted) | 28% (13/46)c | 32% (6/19)c | 26% (7/27)c |
| Intervention | |||
| Supplemental oxygen | 85% (39/46) | 84% (16/19) | 85% (23/27) |
| Non-invasive ventilation (incl HFNOa) | 33% (15/46) | 37% (7/19) | 30% (8/27) |
| Mechanical ventilation | 13% (6/46) | 32% (6/19) | 0% (0/27) |
| IV vasopressors | 18% (8/45) | 32% (6/19) | 8% (2/26) |
| Hemodialysis | 9% (4/46) | 11% (2/19) | 7% (2/27) |
| Agents used for Covid-19 | |||
| Hydroxychloroquine | 4% (2/45) | 11% (2/19) | 0% (0/26) |
| Remdesivir | 26% (12/46) | 5% (1/19) | 41% (11/27) |
| Tocilizumab | 2% (1/45) | 5% (1/19) | 0% (0/26) |
| IVIGb | 4% (2/45) | 0% (0/19) | 8% (2/26) |
| Corticosteroids | 65% (30/46) | 47% (9/19) | 78% (21/27) |
| Convalescent plasma | 7% (3/46) | 5% (1/19) | 7% (2/27) |
| Anticoagulation | 89% (41/46) | 84% (16/19) | 93% (25/27) |
aHigh flow nasal oxygen.
bIntravenous immunoglobulin.
coverall numerical death rate (including non-admitted patients) was 23% (32% in month 1–6 and 18% in month 7–13).